Details of the Drug

General Information of Drug (ID: DM92P0F)

Drug Name
Sisomicin
Synonyms
Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 447.5
Logarithm of the Partition Coefficient (xlogp) -5.1
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 8
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 1 mL/min/kg [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.4 hours [1]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.70337 micromolar/kg/day [2]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [1]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.19 L/kg [1]
Chemical Identifiers
Formula
C19H37N5O7
IUPAC Name
(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
Canonical SMILES
CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CN)N)N)N)O
InChI
URWAJWIAIPFPJE-YFMIWBNJSA-N
InChIKey
1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
Cross-matching ID
PubChem CID
36119
ChEBI ID
CHEBI:9169
CAS Number
32385-11-8
DrugBank ID
DB12604
INTEDE ID
DR2408

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Aminoglycoside phosphotransferase (aph-Ib)
Main DME 		DE5WGIM A0A075C7U3_CAMJU Substrate [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
2 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
3 Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.